Camrelizumab Biosimilar – Anti-PDCD1, PD-1, CD279 mAb – Research Grade

Description of Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb - Research Grade

Introduction to Camrelizumab Biosimilar

Camrelizumab Biosimilar, also known as Anti-PDCD1, PD-1, CD279 monoclonal antibody, is a therapeutic antibody designed to target the programmed cell death protein 1 (PD-1) pathway. This pathway plays a crucial role in regulating the body’s immune response, and abnormalities in this pathway have been linked to various diseases, including cancer and autoimmune disorders.

Structure of Camrelizumab Biosimilar

Camrelizumab Biosimilar is a monoclonal antibody, meaning it is produced from a single clone of immune cells. It is a biosimilar of the original Camrelizumab, which was developed by Jiangsu Hengrui Medicine Co., Ltd. The structure of Camrelizumab Biosimilar is highly similar to the original drug, with minor differences in the manufacturing process. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa.

Mechanism of Action

Camrelizumab Biosimilar works by binding to the PD-1 receptor on the surface of immune cells. This receptor is responsible for regulating the immune response by inhibiting the activation of T cells. When Camrelizumab Biosimilar binds to PD-1, it blocks this inhibitory signal, allowing T cells to become activated and attack cancer cells or other targets. This mechanism is particularly important in the treatment of cancer, as tumors often use the PD-1 pathway to evade the immune system.

Applications of Camrelizumab Biosimilar

The primary application of Camrelizumab Biosimilar is in the treatment of cancer. It has been approved for use in China for the treatment of relapsed or refractory classical Hodgkin lymphoma and advanced or metastatic esophageal squamous cell carcinoma. It is also being studied in clinical trials for the treatment of other types of cancer, including non-small cell lung cancer, gastric cancer, and hepatocellular carcinoma.

In addition to its use in cancer treatment, Camrelizumab Biosimilar is also being investigated for its potential in treating autoimmune disorders. By blocking the PD-1 pathway, it may be able to reduce the activity of the immune system and prevent it from attacking healthy tissues. This could be beneficial in diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.

Research Grade Antibody

Camrelizumab Biosimilar is available as a research grade antibody, meaning it is intended for use in laboratory research and not for human or animal treatment. This allows scientists to study the antibody’s effects on different diseases and explore its potential as a therapeutic agent. The research grade antibody is also used in the development and testing of new biosimilars, ensuring their safety and effectiveness before they can be approved for clinical use.

Conclusion

Camrelizumab Biosimilar is a promising therapeutic antibody that targets the PD-1 pathway and has potential applications in the treatment of cancer and autoimmune disorders. Its structure, mechanism of action, and various applications make it a valuable tool for scientific research and a potential treatment option for patients in the future.

Keywords: Camrelizumab Biosimilar, Anti-PDCD1, PD-1, CD279 monoclonal antibody, therapeutic target, antibody, cancer, autoimmune disorders, research grade

Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb (cat. No.PX-TA1445) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450